Track OPTN and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
OptiNose
777 Township Line Road, Yardley, PA, United States, 19067
IPO
2017
Employees
127
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania. As of May 21, 2025, OptiNose, Inc. operates as a subsidiary of Paratek Pharmaceuticals, Inc.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q1 20254-4
0
Analyst Ratings
3 analysts covering
Hold100%recommend hold
Buy
0
Hold
3
Sell
0